Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Jagsonpal Pharmaceuticals Limited

NSE: JAGSNPHARMPharmaceuticals

Share price

₹231.70

-1.57% close of 8 Oct 2026

Market cap ₹1,506 CrP/E 32.7

Business score

How strong the business is, in one number. The parts behind it are in Pro.

57

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹1,506 Cr

P/E ratio

32.7

P/B ratio

5.6

ROCE

22.7%

ROE

16.7%

Dividend yield

1.7%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹243.9752-week low ₹161.07

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 3.9% over the past year, and 3.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 9.9% to 20.7% over the last four years.

Whether it grew faster than its sector

It grew 3.0% a year against a sector median of 13.1% — 10.1 percentage points slower.

Room to re-rate, or risk of de-rating

At 32.7× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 30.8×, across 5 companies. It is against its own five-year median of 34.0×, the 46th percentile of its own range.

Whether growth justifies the valuation

Priced at 2.0 times its growth rate, on earnings growth of 16%.

Profit growthPrice per ₹1 profitPer 1% growth
Jagsonpal Pharmaceuticals Limited — this one16%/yr32.7×₹2.0
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7
Cipla10%/yr29.6×₹3.0
Dr Reddy's Laboratories-4%/yr30.8×—
Mankind Pharma Limited17%/yr45.7×₹2.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 31 of 130 on returns, 108 of 127 on growth, 56 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 22.7% on capital, ahead of 76% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹191 crore of cash from the business, spent ₹35 crore on plant and equipment, and returned ₹51 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 133 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 59 days for its cash to waiting 11 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

9 of 9 checks clear · 100%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 29 Jul 2026 · Standalone

Revenue

₹82 Cr

Revenue vs last year

+8.8%

Revenue vs last quarter

+28.1%

Net profit

₹13 Cr

Profit vs last year

+22.1%

Profit vs last quarter

+50.6%

Net margin

16.0%

EPS

₹2.00

Earnings call transcript · 30 Jul 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹1,506 Cr
Prev close
₹231.70
52w High
₹265
52w Low
₹155
Enterprise value
₹1,408 Cr
Beta
1.2
Price CAGR 1y
8.0%
Price CAGR 3y
12.0%
Price CAGR 5y
31.0%
Price CAGR 10y
30.0%

Ratios

Return on assets
13.6%
PEG ratio
2.0
P/E ratio
32.7
P/B ratio
5.6
EV / EBITDA
23.5
Industry P/E
38.0
ROCE
22.7%
ROCE 5y average
21.6%
ROE
16.7%
Debt / Equity
0.0
Interest coverage
59.0
Dividend yield
1.7%
ROE 3y average
15.0%
ROE last year
17.0%

Annual P&L

Annual revenue
₹287 Cr
Annual profit
₹43 Cr
Operating margin
20.0%
Net profit margin
15.0%
EBITDA margin
20.2%
Sales growth 3y
6.6%
Sales growth 5y
8.8%
Profit growth 3y
16.0%
Profit growth 5y
21.0%
EPS
₹6.4
Sales growth TTM
4.0%
Profit growth TTM
10.0%
Dividend payout
62.0%

Quarter P&L

Sales latest quarter
₹82 Cr
Profit latest quarter
₹13 Cr
YoY quarterly sales growth
8.8%
YoY quarterly profit growth
18.2%
OPM latest quarter
21.0%

Balance Sheet

Book Value
₹42.5
Face Value
₹2.0
Total debt
₹8 Cr
Total cash
₹106 Cr
Borrowings
₹8 Cr
Reserves / Equity
20.2

Cash Flow

Operating cash flow
₹47 Cr
Free cash flow
₹47 Cr
FCF yield
3.0%
Net cash flow
-₹1 Cr

Shareholding

Promoter holding
69.1%
FII holding
2.3%
DII holding
0.6%
Public holding
28.0%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Jagsonpal Pharma235.4033.01,5531.7013.222.182.28.822.7
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales60584743617574597674736482
Expenses52494441515858506158575365
Material Cost3.495.333.843.952.994.87
Change in Inventories0.74-1.09-0.41-0.310.89-2.29
Purchases of Stock-in-Trade172324232026
Employee Cost171918181623
Other Expenses121513131414
Operating Profit983310161691416161117
OPM %14147.206.14172221151922221721
Other Income2232-2226333133
Exceptional items (within Other Income)-0.2100-2.0800
Interest0000000000000
Depreciation0000122222222
Profit before tax1010557153991417151218
Tax %26252522252517242525252525
Net Profit7744511327111311913
EPS in Rs1.141.140.600.540.811.734.820.991.621.891.641.312
Diluted EPS in Rs0.981.581.871.651.211.98

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales138143144127167159188218237209269287294
Expenses129132138138157150169192203186218229233
Material Cost1816
Change in Inventories-2.13-0.93
Purchases of Stock-in-Trade8089
Employee Cost7171
Other Expenses5054
Operating Profit9126-119919263423515861
OPM %684-96510121411192021
Other Income01130134329281010
Exceptional items (within Other Income)20-2.08
Interest45311110010.961.031
Depreciation3320111211.668.139.449
Profit before tax2414-129922273530705861
Tax %302018-12016222923252125
Net Profit1312-127817192722554345
EPS in Rs0.180.501.81-1.761.101.202.602.884.083.408.346.436.84
Diluted EPS in Rs8.226.31
Dividend Payout %2282-2917155649593062

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
7%
5 years
9%
3 years
7%
TTM
4%

Compounded profit growth

10 years
30%
5 years
21%
3 years
16%
TTM
10%

Stock price CAGR

10 years
30%
5 years
31%
3 years
12%
1 year
8%

Return on equity

10 years
11%
5 years
16%
3 years
15%
Last year
17%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital131313131313131313131313
Reserves828597859198109120146174227263
Borrowings39388845706998
Other Liabilities192225232831353130212932
Total Liabilities154159143130136147164164195217278317
Fixed Assets52522221222226232499485
CWIP000344000000
Investments000001115511000
Other Assets10210812110511010912391170208184231
Total Assets154159143130136147164164195217278317

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity49-3-2311128747355547
Cash from Investing Activity-0-241-3-1-11-2-26-58-25-45-36
Cash from Financing Activity-1-6-34-1-6-1-7-18-0-9-12-12
Net Cash Flow215-624-019-36-112-2-1
Free Cash Flow4640-5301228648359047

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days119106100734549252632191822
Inventory Days17624629530716419113412282685851
Days Payable426056545976827666353740
Cash Conversion Cycle252292339325150164777248533933
Working Capital Days6872154149675532593452911
ROCE %573-1099182025172323

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters696868686868686868676869
FIIs0.380.530.731.102.302.102.102.172.122.122.442.30
DIIs0.820.820.840.840.11000.050.080.150.220.62
Public303030303030303030302928
No. of Shareholders16,04115,78516,28215,74815,63318,47121,08522,89924,65324,89526,26424,181

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +8.3% (₹213.97 → ₹231.70)Brick size ₹9.58 (fixed)Bricks 13
₹175₹200₹232Dec '25May '26
Price moved up one brickPrice moved down one brickLast close ₹231.70 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-98.12inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

22,12,799inr

2026-03-31

News

News and filings about Jagsonpal Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Allylestrenol API
  • Collagen type II peptide
  • Dienogest API
  • Doxycycline hydrochloride API
  • Doxylamine succinate API
  • Dydrogesterone (micronized) API
  • Hydroxyprogesterone caproate API
  • Indomethacin API
  • Lycopene (carotenoid)
  • Methylcobalamin
  • Mifepristone API
  • Myo-inositol / D-chiro-inositol
  • Nandrolone decanoate API
  • Progesterone (micronized/injectable) API
  • Ulipristal acetate API

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE048B01035

News impact

Big market events that reach Jagsonpal Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

4 Sep 2026unspecified₹4
12 Sep 2025unspecified₹2.5
8 Jan 2025split₹0
6 Sep 2024unspecified₹5
21 Aug 2023unspecified₹5
29 Oct 2021interim₹4
22 Sep 2021unspecified₹1
22 Sep 2020unspecified₹0.5

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
24 Sep 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY4,23,870₹241.03
24 Sep 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL4,23,870₹241.20
24 Sep 2026BLITZQUANT RESEARCH LLPBUY3,31,971₹242.60
24 Sep 2026BLITZQUANT RESEARCH LLPSELL3,31,971₹242.74
30 Jul 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL6,08,181₹249.89
30 Jul 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY6,08,181₹249.74
30 Jul 2026MICROCURVES TRADING PRIVATE LIMITEDBUY5,89,936₹251.82
30 Jul 2026MICROCURVES TRADING PRIVATE LIMITEDSELL5,89,936₹252.00
30 Jul 2026SILVERLEAF CAPITAL SERVICES PRIVATE LIMITEDSELL4,12,356₹250.61
30 Jul 2026SILVERLEAF CAPITAL SERVICES PRIVATE LIMITEDBUY4,12,356₹250.43

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.